Priapism Low-Flow Degree in Patient with Chronic Myeloid Leukemia (CML)

Authors

  • Dea Syafira Mahlevi
  • M. Noor Diansyah
  • Merlyna Savitri
  • Putu Niken Ayu Amrita
  • Pradana Zaky Romadhon
  • Ami Ashariati
  • Siprianus Ugroseno Yudho Bintoro

Keywords:

CML, Priapism, Imatinib mesylate, aspiration intracavernous, distal shunting

Abstract

Background: Chronic Myeloid Leukaemia (CML) is a type of cancer caused by disruption of haematopoietic stem cells. CML is a type of Myeloproliferative Neoplasm (MPN). CML is caused by a cytogenetic abnormality involving chromosome 9 and chromosome 22, known as Philadephia (Ph) Chromosome. Case report: A 25-year-old male patient has been diagnosed as Chronic Myelous Leukaemia (CML) for 2 years 2019. The patient has been tested for BCR-ABL1 Quantitative PCR with 63% (IS) results in 2019. Previously, the patient received imatinib but from 2019 to 2021 the patient did not take the medicine regularly. the patient came to the hospital to find that the penis had an erection for 6 hours continuously. Based on anamnesis, physical examination and supporting examination in the form of complete blood, peripheral blood smear, and intracavitary blood gas analysis, we diagnosed the patient with Chronic Myeloid Leukemia  (CML) with accelerated phase accompanied by leukostasis manifesting priapismus (ischemic). As initial management, the patient was given rehydration therapy, imatinib mesylate, hydroxyurea, analgesics, Xanthin oxidase and leukoferesis. Leukoferesis was performed once. Priapismus in the patient reduced slowly during the 14-day treatment Conclusion: Reported a case of a patient with Chronic Myeloid Leukemia (CML) experiencing priapismus with a low flow degree that improved with the administration of imatinib mesylate, hydroxyurea, analgesics, Xanthin oxidase and leukoferesis. Leukoferesis was performed once. The patient's urologist performed intracavernous aspiration and distal shunting with the ebbehoj method.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

References

Burnett AL, Bivalacqua TJ. Priapism: new concepts in medi- cal and surgical management. Urol Clin North Am 2011; 38:185-94.

Baccarani M, and Dreyling M. 2010. Chronic Myeloid Leukaemia: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. Annals of Oncology, 21 (Supplement 5):v165–v167.

Broderick, G.A, Kadioglu, A., Bivalacqua, T.J., Ghanem, H., Nehra, A., Shamloul, R. (2010) Priapism: pathogenesis, epidemiology, and management. J Sex Med;7(1 Pt 2):476-500.

Hasford J, Baccarani M, Hoffmann V, et al. 2011. Predicting Complete Cytogenetic Response and Subsequent Progression-Free Survival in 2060 Patients with CML on Imatinib Treatment: the EUTOS Score. Blood, 118:686–692.

Huang YC, Harraz AM, Shindel AW, Lue TF. Evaluation and management of priapism: 2009 update. Nat Rev Urol 2009; 6:262-71.

Jabbour E, and Kantarjian H. 2018. Chronic Myeloid Leukemia: 2018 Update on Diagnosis, Therapy, and Monitoring. Am J Hematol., 93(3):442-459.

Lange T, Krahl R, Grünhagen Uv, Al-Ali HK, Schwarzer A, Jentsch-Ullrich K, et al. Imatinib (IM) in combination with Hydroxyurea in patients with CML1st CP does not increase molecular response at 18 months compared to IM alone. Final results of the OSHO CML2004 study. Oncol Res Treat. (2017) 40:121–2. doi: 10.1038/sj.leu.2402041

Liesveld JL dan Lichtman MA. 2016. Chapter 89, Chronic Myelogenous Leukemia and Related Disorders, dalam: Kaushansky et al., 2016, Williams Hematology 9th edition. Mc Graw-Hill Education. Hlm 1437-1490.

Loscocco F, visani, G., Galimbreti, S., Curti, A., Isidori, A. 3029. BCR-ABL independent mechanism of resistance in chronic myeloid leukimia. Frontiers in Oncology. 2019 (939): 1-11.

Rodgers R, Latif Z, Copland M. How I manage priapism in chronic myeloid leukaemia patients. Br J Haematol. 2012;158(2):155–64.

Singh H, Orasad BNS, Jagdish, Batra A. Hyperleukocytosis Associated Pulmonary Leukostasis in Acute Leukemia. Journal Association of Physicians India. 2006; 54: 405-7.

Song PH, Moon KH. Priapism: current updates in clinical management. Korean J Urol 2013;54:816-23.

Steinberg MH. Sickle cell anemia, the first molecular disease: overview of molecular etiology, pathophysiology, and therapeutic approaches. Scientific World Journal. 2008;8:1295-1324.

M. R. Minckler, E. Conser, J. J. Figueroa, A. J. Scott, J. Gaither, and R. Amini, “The semantics of priapism and the first sign of chronic myeloid leukemia,” Case Reports in Emergency Medicine, vol. 2017, Article ID 2656203, 3 pages, 2017.

Downloads

Published

2025-05-22

How to Cite

1.
Mahlevi DS, Diansyah MN, Savitri M, Amrita PNA, Romadhon PZ, Ashariati A, Yudho Bintoro SU. Priapism Low-Flow Degree in Patient with Chronic Myeloid Leukemia (CML). J Neonatal Surg [Internet]. 2025May22 [cited 2025Sep.14];14(26S):692-7. Available from: https://www.jneonatalsurg.com/index.php/jns/article/view/6343

Issue

Vol. 14 No. 26S (2025): Journal of Neonatal Surgery

Section

Original Article

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

You are free to:

  • Adapt — remix, transform, and build upon the material for any purpose, even commercially.

Terms:

  • Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
  • No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.